Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MRVL

Go back to Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

Amgen (AMGN) Announces ABP 501 Phase 3 Met Primary Endpoint in RA vs Adalimumab

November 9, 2015 5:31 PM EST

Amgen (NASDAQ: AMGN) presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar candidate ABP 501 with adalimumab in patients with moderate-to-severe rheumatoid arthritis. The results were presented today in an oral presentation at the 2015 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in San Francisco.

The study met the primary endpoint, which was achievement of ACR20 (20 percent or greater improvement in ACR assessment) at week 24. At week 24, 74.6 percent of patients in the ABP 501 group and 72.4 percent in the adalimumab group... More